Anergis completed Phase II for AllerT, a novel treatment for pollen allergies

02/04/2015 - 3 minutes

Anergis announced treatment completion of its Phase II clinical trial of AllerT, a novel long-peptide immunotherapeutic to treat birch pollen allergies. Anergis’ approach uses synthetic, pharmaceutical-grade Contiguous Overlapping Peptide (“COP”), peptides of 40-80 amino-acids which are safer (no risk of immediate allergic reaction) and can elicit a faster immune response than the allergenic proteins they are derived from.

Allergies are the most prevalent and fastest growing chronic conditions in the industrialized world affecting over 500 million people. The only curative therapy of allergies available today, known as “desensitization” or conventional Allergy Immunotherapy (AIT), is the process of inducing tolerance to the allergen. It requires 3-5 years of treatment and exposes patients to the risk of immediate (<30 min) anaphylactic reactions which can be life-threatening. With its ultra-fast COP allergy immunotherapy, Anergis is shaping the future of allergy treatment.

COPs which reproduce the complete amino acid sequence of the allergen in separate synthetic long peptides. COP allergy immunotherapeutics do not cross-react with IgE, the antibody class responsible for eliciting allergic hypersensitivity.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT Do you want to remove this advert? Become a member!
ADVERTISEMENT Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member